Recros Medica Closes $14 Million Series A Financing

SAN DIEGO, CA November 19, 2019 Recros Medica, Inc. today announced the closing of a $14 million Series A preferred stock financing. Recros is an aesthetic company focused on developing medical devices to reduce skin laxity and improve focal contouring via its Nuvellus® Focal Contouring system. The Nuvellus® platform, based on the Company’s proprietary rotational fractional resection technology, may offer a novel procedure that produces results from a single treatment. Nearly 100 subjects have been treated in 4 IRB-approved clinical trials, the Company is currently planning a pivotal clinical study. The company is also developing Nuvellus® to facilitate autologous dermal transfer, as a natural alternative to commercial dermal fillers.

This Series A preferred stock financing was completed with Haohai Healthcare Holdings Co., Limited of Shanghai, China as the sole investor. Haohai is a rapidly growing leading pharmaceutical and medical device company in China with a significant focus in medical aesthetics. Included with this investment is the right for Haohai to negotiate for China market rights for the Nuvellus® Focal Contouring system on mutually agreeable terms. With this investment, Recros Medica has now raised a total of $36 million. These funds will be used to continue the development of the Nuvellus® Focal Contouring system, conduct a pivotal clinical study and achieve FDA clearance to commercialize the system in the U.S.

“We are pleased to work with Haohai on this significant investment in Recros Medica; we are also excited about their potential to market the Nuvellus® Focal Contouring system in China. This investment underscores the potential of Nuvellus® as a novel medical aesthetic treatment with global appeal in many patient types,” stated Tom Albright, president and CEO of Recros Medica.

Share this news article

Share on facebook
Share on twitter
Share on linkedin
Share on email